

Supplementary Online Content

Tsai CJ, McBride SM, Riaz N, et al. Evaluation of substantial reduction in elective radiotherapy dose and field in patients with human papillomavirus–associated oropharyngeal carcinoma treated with definitive chemoradiotherapy. *JAMA Oncol*. Published online January 20, 2022. doi:10.1001/jamaoncol.2021.6416


eFigure. Select Examples of Target Volume Delineation

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure. Select Examples of Target Volume Delineation


S1A. Example of a patient who received 50 Gy dose around primary tumor. Patient underwent PET/CT and MRI simulation with image fusion.

Red: GTV70_primary; Blue: CTV50; Yellow: CTV30. Rules for expansion to PTV were outlined in the Methods section of the manuscript.



S1B. Example of a patient who received 50 Gy dose to indeterminate lymph nodes. Patient underwent PET/CT and MRI simulation with image fusion.

Red: GTV70_primary; Blue: GTV50_nodes; Yellow: CTV30. Rules for expansion to PTV were outlined in the Methods section of the manuscript.



S1C. Example of a patient treated with our standard two dose levels. Patient underwent PET/CT and MRI simulation with image fusion.

Red: GTV70_primary and GTV70_nodes; Yellow: CTV30. Rules for expansion to PTV were outlined in the Methods section of the manuscript.

